Crossmark

Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol

Crossref DOI link: https://doi.org/10.1186/s13063-022-07051-9

Published Online: 2023-01-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Eleftheriou, Despina https://orcid.org/0000-0002-5312-2269
Moraes, Yolanda Collaco

Purvis, Cara

Pursell, Molly

Morillas, Marta Merida

Kahn, Robin

Mossberg, Maria

Kucera, Filip

Tulloh, Robert

Standing, Joseph F.

Swallow, Veronica

McCormack, Rachael

Herberg, Jethro

Levin, Michael

Wan, Mandy

Klein, Nigel

Connon, Roisin

Walker, Ann Sarah

Brogan, Paul
Funding

Funding for this research was provided by:

Innovative Medicines Initiative (777389)
License Information

Text and Data Mining valid from 2023-01-26

Version of Record valid from 2023-01-26
More Information

Article History

Received: 28 October 2022

Accepted: 23 December 2022

First Online: 26 January 2023

Declarations

:

: Ethical approval has been provided for the following countries: Austria, Belgium, Czechia, Estonia, Finland, France, Netherlands, Italy, Spain, Sweden and the UK.

: Informed consent forms and other related documentation given to participants and authorised surrogates is available upon request from .

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below